Brief: Xbrane: Ambition To Generate Positive Operating Cash Flow Monthly By Late 2023/Early 2024

Xbrane Biopharma AB

17/05/2021 06:42

May 17 (Reuters) - Xbrane Biopharma AB  XBRANE.ST :
    * ANNOUNCED ON SUNDAY AMBITION TO GENERATE POSITIVE
OPERATING CASH
FLOW MONTHLY BY LATE 2023/EARLY 2024
    * SAYS IS ON TRACK TOWARDS REGULATORY SUBMISSION FOR
XLUCANE™
(LUCENTIS® BIOSIMILAR CANDIDATE) IN EU Q3 AND US Q4 2021
    * XBRANE HAS AN AMBITION TO GENERATE +100M EURO ANNUALLY IN
NET-INCOME THREE YEARS AFTER LAUNCH  
    * TO INITIATE ONE NEW BIOSIMILAR DEVELOPMENT PROGRAM PER
YEAR
    * HAS ESTABLISHED A NEW BIOSIMILAR DEVELOPMENT LAB 
   

    
 Source text for Eikon:  urn:newsml:reuters.com:*:nMFN8n4FXZ
    
 Further company coverage:  XBRANE.ST  
   


 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))